Medscape Medical News (Oncology)
Neil Osterwell
Sept. 16, 2013
A comprehensive lifestyle intervention might help prostate cancer
patients live to be longer in the tooth and in the telomere, suggest
results of a very small pilot study reported online in The Lancet Oncology.
Among 35 men with biopsy-proven, low-risk prostate cancer who opted
for active surveillance, a comprehensive lifestyle intervention
including diet, activity, stress management, and support was
associated with lengthening of telomeres over 5 years compared with a
loss of telomere length among controls, report Dean Ornish MD,
director of the Preventive Medicine Research Institute, in Sausalito,
California, and colleagues.
Read the full Medscape report
(free sign-up may be required)
Friday, September 20, 2013
FDA OKs New Device to Treat BPH
Medscape Medical News
Mark Crane
Sept. 13, 2013
The US Food and Drug Administration (FDA) today authorized the marketing of the UroLift system, the first permanent implant to relieve low or blocked urine flow in men aged 50 years and older with an enlarged prostate.
The UroLift system relieves the urine flow by pulling back the prostate tissue that is pressing on the urethra.
"The UroLift provides a less invasive alternative to treating [benign prostatic hyperplasia] than surgery," Christy Foreman, director of the Office of Device Evaluation at the FDA's Center for Devices and Radiological Health, said in a release. "This device also may offer relief to men who cannot tolerate available drug therapies."
Read the full Medscape report
(Free sign-up may be required)
Mark Crane
Sept. 13, 2013
The US Food and Drug Administration (FDA) today authorized the marketing of the UroLift system, the first permanent implant to relieve low or blocked urine flow in men aged 50 years and older with an enlarged prostate.
The UroLift system relieves the urine flow by pulling back the prostate tissue that is pressing on the urethra.
"The UroLift provides a less invasive alternative to treating [benign prostatic hyperplasia] than surgery," Christy Foreman, director of the Office of Device Evaluation at the FDA's Center for Devices and Radiological Health, said in a release. "This device also may offer relief to men who cannot tolerate available drug therapies."
Read the full Medscape report
(Free sign-up may be required)
Complications of Robotic Surgery Underreported
Medscape Medical News
Robert Lowes
Sept 05, 2013
More injuries and deaths are linked to da Vinci robotic surgery than meet the eye, according to a new study published online August 27 in the Journal for Healthcare Quality.
As a result, "we're not learning from our performance," study coauthor Martin Makary, MD, MPH, told Medscape Medical News.
Between January 1, 2000, and August 1, 2012, the US Food and Drug Administration (FDA) received 245 adverse event (AE) reports related to the controversial da Vinci robotic surgical system, made by Intuitive Surgical. Scouring federal court records and media accounts, Dr. Makary and colleagues found 5 more cases that were never reported. They also discovered that 3 reported cases were problematic. One was submitted 930 days after the surgery, and another 292 days after. The latter case, as well as a third dubious one, was submitted to the FDA only after a media report of the patient's death appeared.
Read the full Medscape report
Robert Lowes
Sept 05, 2013
More injuries and deaths are linked to da Vinci robotic surgery than meet the eye, according to a new study published online August 27 in the Journal for Healthcare Quality.
As a result, "we're not learning from our performance," study coauthor Martin Makary, MD, MPH, told Medscape Medical News.
Between January 1, 2000, and August 1, 2012, the US Food and Drug Administration (FDA) received 245 adverse event (AE) reports related to the controversial da Vinci robotic surgical system, made by Intuitive Surgical. Scouring federal court records and media accounts, Dr. Makary and colleagues found 5 more cases that were never reported. They also discovered that 3 reported cases were problematic. One was submitted 930 days after the surgery, and another 292 days after. The latter case, as well as a third dubious one, was submitted to the FDA only after a media report of the patient's death appeared.
Read the full Medscape report
Subscribe to:
Posts (Atom)